1Mancia G,De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. Eur Heart J, 2007,28(12):1462-1536.
4Weir RA, Mark PB, Petrie CJ,et al. Left ventficular remodeling after acute myocardial infarction: does eplerenone have an effect? [J]. Am Herat J,2009,157(6): 1008 - 1096.
5Solomon SD, Appelbaum E, Manning W J, et al. Effect of the di- rect Relfin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventrieular mass in patients with hylperten- slon and left ventrieular hypertrophy[J]. Circulation, 2009 , 119(4) : 530-537.
6Ball CJ,Wilson DP, Turner SP, et al. Heterogeneity of L- and T- channels in the vasculature: rationale for the efficacy of combined L- and T-blockade[J]. Hypertension,2009,53(4) :654 - 660.
二级参考文献8
1Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD[ J]. Eur Respir J,2008,32 : 1371 - 1385.
3Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD : epidemiology, significance, and management [ J ]. Chest, 2010,137 (6) :39S-51S.
4Rietema H, Holverda S, Bogaard HJ, et al. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity [ J ]. Eur Respir J ,2008,31:759 - 764.
5Barnes PJ. Fulure treatments for chronic obstructive pulmonary, dis- ease and its comorbidities [ J ]. Proc Am Thorac Soc, 2008,5 : 857 - 864.
6Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and fonner smokers [ J ]. Chest ,2007,132 : 1764 - 1771.
7Hoeper MM. Treating pulmonary hypertension in COPD:where do we start? [J]. Eur Respir J,2008,32:541 -542.
8Galie N, Hoeper MM, Humbert M,et al. Guidelines for the diagno- sis and treatment of pulmonary hypertension [ J ]. Eur Respir J, 2009,34 : 1219 - 1263.
3Peat A J, Townsend C, Craig McKay M,et al. 3-Trifluoromethyl- 4-nitro-5-arylpyrazoles are novel K(ATP) channel agonists [ J]. Bioorg Med Chem Lett,2004,14:813 .
4Nielsen F E, Ebdrup S, Jensen A F, ct al. New 3-alkvlamino- 4H-thieno-1, 2, 4-thiadiazine 1, 1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells [ J]. J Med Chem ,2006,49:4127.
5Carosati E, Mannhold R, Wahl P, et al. Virtual screening for novel openers of pancreatic K(ATP) channels[ J]. J Med Chem, 2007,50:2117.
6Peat A J, Townsend C, Worly J F, et al. Synthesis and evalua- tion of 7-substituted-3-cyclobutylamino-4H-1,2,4-benzothiadia- zine-1,1-dioxide derivatives as K (ATP) channel agonists [ J ]. Bioorg Med Chem Lett, 2002,12: 2977.
7Zhang X, Qiu Y, Li X, et al. Discovery and structure-activity relationships of a novel series of benzopyran-based K (ATP) openers for urge urinary incontinence [ J ]. Bioorg Med Chem, 2009,17:855.
8Manaswini J, V Badireenath K, Surya N R, et al. Elucidation of the inhibitory effect of phytochemicals with Kit6. 2 wild-type and mutant models associated in type-1 diabetes through molecular docking approach[J]. Genome Inform, 2014,12(4) :283.
9Yadav D, Paliwal S, Yadav R, et al. Identification of novel HIV 1-protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening [ J ]. PLoS ONE, 2012, 7(11) : e48942.
10Sundarapandian T, Shalini J, Sugunadevi S, et al. Potential vir- tual lead identification in the discovery of renin inhibitors : appli- cation of ligand and structure-based pharmacophore modeling ap- proaches [ J ]. Eur J Med Chem,2011,46 (6) :2469.
